These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

832 related items for PubMed ID: 30920593

  • 41. Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy.
    Ceci F, Rovera G, Iorio GC, Guarneri A, Chiofalo V, Passera R, Oderda M, Dall'Armellina S, Liberini V, Grimaldi S, Bellò M, Gontero P, Ricardi U, Deandreis D.
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3257-3268. PubMed ID: 35217883
    [Abstract] [Full Text] [Related]

  • 42. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jul; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 43. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
    Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, Vasanawala S, Gambhir SS, Iagaru A.
    J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U.
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients.
    Celli M, De Giorgi U, Caroli P, Di Iorio V, Fantini L, Rossetti V, Foca F, Nicolini S, Giganti M, Paganelli G, Matteucci F.
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):87-94. PubMed ID: 32588090
    [Abstract] [Full Text] [Related]

  • 49. Diagnostic Accuracy of Multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer.
    Muehlematter UJ, Burger IA, Becker AS, Schawkat K, Hötker AM, Reiner CS, Müller J, Rupp NJ, Rüschoff JH, Eberli D, Donati OF.
    Radiology; 2019 Nov; 293(2):350-358. PubMed ID: 31502937
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET.
    Emmett L, van Leeuwen PJ, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, Kneebone A, Eade T, Fogarty G, Jagavkar R, Nguyen Q, Ho B, Joshua AM, Stricker P.
    J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer.
    Afaq A, Bomanji J.
    Br Med Bull; 2018 Dec 01; 128(1):37-48. PubMed ID: 30272121
    [Abstract] [Full Text] [Related]

  • 56. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
    Kabasakal L, Demirci E, Nematyazar J, Akyel R, Razavi B, Ocak M, Aygun A, Obek C, Kural AR.
    Nucl Med Commun; 2017 Feb 01; 38(2):149-155. PubMed ID: 27893589
    [Abstract] [Full Text] [Related]

  • 57. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.
    Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.
    J Nucl Med; 2018 Feb 01; 59(2):230-237. PubMed ID: 29123013
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications.
    Giovacchini G, Giovannini E, Riondato M, Ciarmiello A.
    Curr Radiopharm; 2018 Feb 01; 11(1):4-13. PubMed ID: 29090673
    [Abstract] [Full Text] [Related]

  • 60. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
    Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR.
    J Nucl Med; 2017 Dec 01; 58(12):1956-1961. PubMed ID: 28522741
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.